Splet15. feb. 2024 · INTRODUCTION. Elevated levels of circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) are associated with increased low-density lipoprotein (LDL) and worse cardiovascular outcomes. Antibodies to PCSK9 have been approved by regulatory agencies for the treatment of individuals with inadequately treated levels of … SpletThe PCSK9 inhibitors alirocumab (Praluent®) and evolocumab (Repatha®) are available under the High Tech Arrangement. A Managed Access Protocol is in place for the PCSK9 …
Clinical Guidance - Criteria For Use - Pharmacy Benefits …
Splet18. okt. 2024 · The initial approach for PCSK9 inhibition was the development of two fully human monoclonal antibodies (mAbs), alirocumab and evolocumab, that block the interaction between circulating PCSK9 ... Splet06. apr. 2024 · PCSK9 inhibitor therapy: payer approvals and rejections, and patient characteristics for successful prescribing. Circulation. 2024; 136:2210–2219. DOI: 10.1161/CIRCULATIONAHA.117.028430. Link Google Scholar can lineman take a handoff
Prior Authorization Criteria - bcbsal.org
SpletClinical Design and Innovation National Clinical Programmes Medicine Management PCSK9 Inhibitors Repatha (evolocumab) 140 mg solution for injection in Sureclick pre-filled pen … Splet06. apr. 2024 · Background Few adults at high risk for atherosclerotic cardiovascular disease events use a PCSK9i (proprotein convertase subtilisin/kexin type 9 inhibitor). Methods and Results Using data from the ... Splet10. sep. 2024 · PCSK9 in complex with compound 19 PDB DOI: 10.2210/pdb7S5G/pdb Classification: PROTEIN BINDING,HYDROLASE Organism (s): Homo sapiens, synthetic construct Expression System: Spodoptera frugiperda Mutation (s): No Deposited: 2024-09-10 Released: 2024-11-03 Deposition Author (s): Orth, P. Funding Organization (s): Not … fix auto macarthur